LUMAKRAS is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
LUMAKRAS recommended dose: 960 mg orally, once daily1
LUMAKRAS can be taken with or without food1
Patients should take the daily dose of LUMAKRAS at the same time each day1
LUMAKRAS 320 mg tablets have a beige color and are supplied in one bottle containing 90 tablets
LUMAKRAS tablets are comparable in size to a dime2,*
*Tablet as seen on screen may not reflect actual size; scale to dime is accurate.
LUMAKRAS 120 mg tablets have a yellow color and are supplied in one bottle containing 240 tablets
LUMAKRAS tablets are comparable in size to a dime2,*
*Tablet as seen on screen may not reflect actual size; scale to dime is accurate.
Recommended dose reductions1
LUMAKRAS and other drugs1
ALT, alanine transaminase; AST, aspartate transaminase; BCRP, breast cancer resistance protein; ECOG PS, Eastern Cooperative Oncology Group performance status; ILD, interstitial lung disease; P-gp, P-glycoprotein; PI, prescribing information; PPI, proton pump inhibitor; ULN, upper limit of normal.
Hepatotoxicity
Interstitial Lung Disease (ILD)/Pneumonitis
Most common adverse reactions
Drug interactions
INDICATION
LUMAKRAS is indicated for the treatment of adult patients with KRAS G12C‑mutated locally advanced or metastatic non‑small cell lung cancer (NSCLC), as determined by an FDA‑approved test, who have received at least one prior systemic therapy.
This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Please see full Prescribing Information.
Important Safety Information
Hepatotoxicity